Presentation is loading. Please wait.

Presentation is loading. Please wait.

Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

Similar presentations


Presentation on theme: "Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD"— Presentation transcript:

1 Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD
Is Weight Gain Associated with Risk of Diabetes Mellitus In HIV Infected Individuals Initiating Combination Antiretroviral Therapy (cART)? 2012 Final Presentation Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD

2 Weight and HIV Thanks to combination Antiretroviral Therapy (cART):
HIV-associated wasting is rare Obesity epidemic extends to HIV population Median weight gain after 12 mos of cART 6.6 lbs Long-term health implications not yet characterized

3 Weight, Diabetes, and HIV
Obesity and weight gain are risk factors for diabetes in HIV- Study questions: Do BMI and weight change predict incident diabetes among HIV positive patients receiving cART? Do BMI and weight change have a different association with incident diabetes among HIV positive and negative patients?

4 Study Design Veterans Aging Cohort Study (VACS) Virtual Cohort
Patient eligibility criteria Recorded BMI at baseline and 1 year later Recorded blood glucose test after baseline HIV positive patients were cART naïve (HIV-1 RNA >500 copies/mL) Prevalent diabetes exclusion criteria Baseline BMI categories

5 Variables & Statistical Analysis
Primary Predictor Variables: Weight gain over 12 months after start date (5 lb increments) Outcome: Incident diabetes (A1C ≥ 7.0 %) Statistical Model: Cox Proportional Hazards cART initiation date HIV+ DM? Weight Change Time until event Baseline BMI 12 months First available BMI HIV+ 5

6 Baseline patient characteristics
HIV - HIV + N = 7766 N = 2939 Age mean (SD) 50 (10) 48 (10) Sex % Male 97.1 96.8 Race (%) White 43.7 35.6 Black 48.1 55.6 Hispanic/Other 6 CD4 cells/mm3, median (IQR) -- 192 (157) HIV-1 RNA log copies/mL, median (IQR) 5.3 (5) BMI 29 (6) 24 (5) BMI (%) Underweight <18.5 1.6 7.0 Normal 18.5 to <25 25.4 54.9 Overweight 25 to <30 36.1 28.6 Obese >= 30 36.9 9.5 Smoking (%) Never 11.0 13.0 Current 32.9 35.5 Former 7.7 8.1 Unknown 48.5 43.5 Present Hepatitis C Infection 19.7 35.7

7 Weight Change Over 12 Months by Baseline BMI
Weight change over 12 months following start date Lost > 5 lbs Remained within ± 5 lbs Gained > 5 lbs Baseline BMI

8 Incidence of Diabetes by BMI at Baseline and Weight Gain Over 12 Months
# DM Events HIV - 13 11 HIV + 2 14 37 38 43 23 8 12 16 73 82 64 4 9

9 Multivariate Risk of Incident Diabetes
Multivariate Risk of Incident Diabetes Hazard Ratio 95% CI p value Sex Male 1.03 (0.73,1.45) 0.88 Race Black 1.26 (1.12,1.43) 0.0002 Hispanic 1.13 (0.88,1.46) 0.34 Other 1.20 (0.82,1.76) Age Per 5 years 1.09 (1.05,1.12) <.0001 HIV status HIV positive status 0.68 (0.56,0.83) 0.0001 Hepatitis C status Hep C positive 1.19 (1.04,1.37) 0.02 Weight change (per 5 lbs) HIV-negative 1.04 (1.02,1.07) HIV-positive 1.11 (1.07,1.15) Baseline BMI Underweight 0.67 (0.37,1.21) 0.18 Overweight 1.86 (1.55,2.25) Obese 4.61 (3.86,5.50)

10 Summary HIV+ gained more weight after cART initiation than HIV-
HIV protective against risk of diabetes after adjustment for weight and other risk factors Per 5 lb weight gain, HIV-postive patients may be at increased risk for incident diabetes

11 Conclusions / Questions
Could HIV be continuing to exert a physiologic burden decreasing risk of diabetes? Future investigations: Other indicators of metabolic syndrome including cholesterol, triglycerides, and blood pressure

12 Clinical Conclusion This analysis suggests that people initiating cART who are not underweight should avoid weight gain in excess of 10 lbs

13 Limitations Among HIV-positives, those who were normal weight and overweight at baseline powered our analysis Cohort primarily men – may not be able to draw conclusions to women and demographically dissimilar populations Weight change over only first12 months after cART initiation – what happens longer term? Incident diagnostic diabetes criteria: AIC ≥ 7.0%

14 Acknowledgments Dr. Amy Justice Jan Tate VACS Project Team
Amanda, Barbara, Dr. Aronson We would also like to acknowledge the veterans who participate in the Veterans Aging Cohort Study, the study contributors and staff at each of our sites and the Veterans Affairs Healthcare System. Without the commitment and care of these individuals, this research would not be possible.


Download ppt "Melissa Herrin, Jan Tate ScD, MPH & Amy Justice, MD, PhD"

Similar presentations


Ads by Google